Envoy Medical

Momentum continues at Envoy Medical (NASDAQ: COCH). We reported our Corporate and Financial Highlights for the Quarter ending June 30, 2026, including reaching an important milestone with the submission of the first module of our FDA Premarket Approval (PMA) application for the investigational Acclaim® Cochlear Implant. We also noted continued advancement of our pivotal clinical trial and shared positive 12-month clinical data on the first 10 participants in Stage 1. We remain focused on advancing what we believe could become the first fully implanted cochlear implant available to patients. We are committed to pushing hearing technology beyond the status quo and improving quality of life for people with hearing loss. Learn more here: https://hubs.li/Q04t2ZD30 CAUTION: The fully implanted Acclaim Cochlear Implant is an investigational device. Limited by Federal (or United States) law to investigational use.

Clinical Momentum Update! Envoy Medical® Inc. (NASDAQ: COCH) has now reached the 3-month visit milestone for all 56 patients enrolled in the pivotal trial of the investigational Acclaim® fully implanted cochlear implant. This milestone reflects continued progress toward a potential FDA PMA submission and our broader mission to advance fully implanted hearing technology. We are grateful to the patients, investigators, and clinical teams helping move this important work forward. Learn more here: https://hubs.li/Q04qw4pZ0 CAUTION The fully implanted Acclaim Cochlear Implant is an investigational device. Limited by Federal (or United States) law to investigational use.

Envoy Medical (NASDAQ: COCH) | Acclaim® Pivotal Trial – 12-Month Stage 1 Update We’re pleased to share encouraging 12‑month data from the first 10 participants in Stage 1 of our pivotal clinical trial evaluating the investigational, fully implanted Acclaim® cochlear Implant. Key Stage 1 interim data for first 10 participants: • CNC word recognition improved to 53.2% at 12 months, up from 15.2% pre-implantation (+38.0 percentage points) • No serious adverse events were reported through 12 months Stage 2 enrollment is progressing as planned. All Stage 2 participants have completed their 1-month visit, with many already through their 3- and 6-month follow-up visits. We anticipate completion of 12-month data collection for all Stage 2 participants by early Q2 2027, followed by a PMA submission to the FDA anticipated a few months later. Envoy Medical CEO Brent Lucas shared: “While the study remains ongoing and these interim results are preliminary, these data reinforce our conviction that the future of cochlear implants is in fully implanted devices using Invisible Hearing® technology.” Learn more here: https://hubs.li/Q04pvR9T0 CAUTION The fully implanted Acclaim Cochlear Implant is an investigational device. Limited by Federal (or United States) law to investigational use.

As you celebrate the Fourth of July, don't forget to protect your hearing. Fireworks can exceed 150dB - loud enough to cause permanent hearing damage. Wearing hearing protections and keeping a safe distance can help preserve your hearing for years to come. Wishing everyone a safe and happy independence day!

Envoy Medical (NASDAQ: COCH) is pleased to announce submission of the first module of our Modular PMA application to the U.S. Food and Drug Administration for our investigational Breakthrough Device-designated Acclaim® cochlear implant. This submission marks an important regulatory milestone and begins a structured pathway designed to support earlier FDA engagement and review with a final clinical module submission being targeted for Q2 2027. We believe the modular PMA approach strengthens visibility into our progress, defines important milestones, and helps us focus on advancing a differentiated, fully implanted hearing solution for people interested in Invisible Hearing® technology through the regulatory review process. Learn more here: https://hubs.li/Q04n6SlM0 CAUTION The fully implanted Acclaim Cochlear Implant is an investigational device. Limited by Federal (or United States) law to investigational use.  

Healthy Vision Month highlights the importance of sight—but in practice, vision rarely operates in isolation. In clinical populations, vision and hearing loss frequently co-occur—and when they do, the impact is not additive, it’s functional. If a patient has vision loss, they rely more heavily on hearing for: - Communication - Environmental awareness - Safety cues If a patient has hearing loss, they rely more heavily on vision for: - Speechreading and visual context - Navigation - Social engagement When both systems are impaired, that compensation mechanism breaks down. Patients experience: - Reduced ability to interpret environmental cues - Increased cognitive load during communication - Higher risk of falls and functional decline - Greater likelihood of social isolation Shared risk factors—particularly in older adults—include: - Diabetes - Cardiovascular disease - Neurologic conditions - Age-related degeneration This is why dual sensory screening matters. Not just to identify two conditions—but to understand how they interact. Healthy vision—and hearing—means preserving the sensory redundancy patients depend on every day. #patientcenteredcare #HearingInnovation #PatientEducation

We’re pleased to share that Brent Lucas, CEO of Envoy Medical (NASDAQ: COCH), will present at two investor events on June 25, 2026: the Virtual Life Sciences Investor Forum and the Biotech Webull Webinar Panel. As a hearing health company pioneering fully implanted hearing solutions, Envoy Medical remains focused on advancing innovation that may improve access, usability, compliance, and quality of life for people with hearing loss. We invite investors and interested stakeholders to tune in on June 25 to learn more about our progress and vision. #EnvoyMedical #NASDAQ #COCH #InvestorRelations #MedTech #HearingHealth CAUTION The fully implanted Acclaim Cochlear Implant is an investigational device. Limited by Federal (or United States) law to investigational use.

Don't miss Our CEO Brent Lucas presenting at the Planet Microcap Conference tomorrow in Las Vegas, Nevada. The event is free, and you can participate in the presentation virtually. To sign up for the Webcast: https://hubs.li/Q04lzdQZ0 CAUTION The fully implanted Acclaim Cochlear Implant is an investigational device. Limited by Federal (or United States) law to investigational use. As always, future milestones remain subject to development, regulatory, and execution of progress. #EnvoyMedicalUpdate #HearingInnovation #InvisibleHearing

Millions of adults in the US qualify for cochlear implants, yet many remain untreated due to reluctance to wear a traditional external device on or around the ear. At Envoy Medical (NASDAQ: COCH), we're working to change that. Our investigational Acclaim® cochlear implant is a first-of-its-kind, fully implanted hearing device, placed entirely beneath the skin, leveraging the ear's natural anatomy to capture sound. Our Invisible Hearing® technology is designed to support patients who are not interested in conventional systems. We believe that's a significant, underpenetrated market opportunity. Envoy CEO Brent Lucas shares an update on our pivotal study progress and PMA submission timeline: https://hubs.li/Q04lcxQJ0 CAUTION The fully implanted Acclaim Cochlear Implant is an investigational device. Limited by Federal (or United States) law to investigational use. #EnvoyMedical #HearingInnovation #EnvoyMedicalUpdate

At Envoy Medical (NASDAQ: $COCH), we are advancing a differentiated vision in hearing healthcare centered on fully implanted, Invisible Hearing® technology, and fully implanted innovation, including our investigational fully implanted Acclaim® cochlear implant.. In a recent interview with Planet MicroCap, our CEO Brent Lucas discussed our progress across several important areas, including pivotal study execution, the anticipated timeline for PMA submission, and potential value catalysts ahead. The conversation also highlights what makes our technology distinct and why we believe fully implanted hearing devices could represent an important shift in hearing health. For investors following med-tech innovation, this interview offers a look at our strategic direction, development milestones, and the longer-term opportunity we are working to build. Watch the interview here: https://hubs.li/Q04kQjJ50 CAUTION The fully implanted Acclaim Cochlear Implant is an investigational device. Limited by Federal (or United States) law to investigational use. As always, future milestones remain subject to development, regulatory, and execution of progress. #EnvoyMedicalUpdate #HearingInnovation #InvisibleHearing